Furthermore, according to the National Comprehensive Cancer Network Guideline (version 1.2021), p53 IHC is recommended for molecular subtype evaluation in patients with endometrioid carcinoma as a surrogate marker of TP53 mutation status. This evidence concerns the gene TP53 and endometrioid adenocarcinoma.